XML 24 R4.htm IDEA: XBRL DOCUMENT v3.20.4
Consolidated Statements of Operations - USD ($)
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Revenues:      
Total revenues $ 7,411,220 $ 4,111,930 $ 30,481,897
Operating expenses:      
Research and development 94,245,436 88,017,319 95,257,876
General and administrative 37,247,828 27,203,156 29,315,159
Total operating expenses 131,493,264 115,220,475 124,573,035
Loss from operations (124,082,044) (111,108,545) (94,091,138)
Other income (expense):      
Interest income 3,311,846 2,605,981 2,264,747
Interest expense (8,702,450) (7,948,539) 0
Change in fair value of common stock warrants 0 0 360,795
Change in fair value of derivative liability (75,670,977) (1,763,652) 0
Gain (loss) on investment in affiliated entities 36,556,658 (3,090,557) (1,988,567)
Net unrealized gain on available-for-sale equity securities 1,695,497 0 0
Other income (expense), net (704,896) 496,200 (1,343,856)
Gain on deconsolidation of Geneos 4,121,075 0 0
Net loss before income tax benefit/(provision for income tax) (162,890,304) (120,809,112) (94,798,019)
Income tax benefit (provision for income taxes) 0 257,335 (2,169,811)
Share in net loss of Geneos (4,584,610) 0 0
Net loss (167,474,914) (120,551,777) (96,967,830)
Net loss attributable to non-controlling interest 1,063,757 1,192,558 0
Net loss attributable to Inovio Pharmaceuticals, Inc. $ (166,411,157) $ (119,359,219) $ (96,967,830)
Net loss per share attributable to Inovio Pharmaceuticals, Inc. stockholders      
Basic and diluted (in USD per share) $ (1.07) $ (1.21) $ (1.05)
Weighted average number of common shares outstanding      
Basic and diluted (in shares) 155,126,857 98,717,999 92,539,997
Convertible Bonds      
Other income (expense):      
Gain (loss) on extinguishment of debt $ (8,177,043) $ 0 $ 0
6.50% Convertible Senior Notes Due 2024      
Other income (expense):      
Gain (loss) on extinguishment of debt 8,762,030 0 0
Revenue under collaborative research and development arrangements      
Revenues:      
Total revenues 5,170,586 3,636,945 29,860,785
Revenue under collaborative research and development arrangements from affiliated entities      
Revenues:      
Total revenues 1,453,730 235,649 449,524
Other revenue      
Revenues:      
Total revenues 786,904 237,536 171,588
Other revenue from affiliated entities      
Revenues:      
Total revenues $ 0 $ 1,800 $ 0